241 related articles for article (PubMed ID: 18620056)
1. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
Lota RK; Dhanani S; Owen CP; Ahmed S
Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
[TBL] [Abstract][Full Text] [Related]
4. Effects of methoxychlor and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase-3 activities in human and rat testes.
Hu GX; Zhao B; Chu Y; Li XH; Akingbemi BT; Zheng ZQ; Ge RS
Int J Androl; 2011 Apr; 34(2):138-44. PubMed ID: 20522127
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
[TBL] [Abstract][Full Text] [Related]
6. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
7. Effects of phthalates on 3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase 3 activities in human and rat testes.
Yuan K; Zhao B; Li XW; Hu GX; Su Y; Chu Y; Akingbemi BT; Lian QQ; Ge RS
Chem Biol Interact; 2012 Feb; 195(3):180-8. PubMed ID: 22214983
[TBL] [Abstract][Full Text] [Related]
8. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances.
Zhao B; Hu GX; Chu Y; Jin X; Gong S; Akingbemi BT; Zhang Z; Zirkin BR; Ge RS
Chem Biol Interact; 2010 Oct; 188(1):38-43. PubMed ID: 20619251
[TBL] [Abstract][Full Text] [Related]
10. The (+)- and (-)-gossypols potently inhibit both 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 in human and rat testes.
Hu GX; Zhou HY; Li XW; Chen BB; Xiao YC; Lian QQ; Liang G; Kim HH; Zheng ZQ; Hardy DO; Ge RS
J Steroid Biochem Mol Biol; 2009 May; 115(1-2):14-9. PubMed ID: 19429456
[TBL] [Abstract][Full Text] [Related]
11. 6-Hydroxybenzothiophene ketones: potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) owing to favorable molecule geometry and conformational preorganization.
Miralinaghi P; Schmitt C; Hartmann RW; Frotscher M; Engel M
ChemMedChem; 2014 Oct; 9(10):2294-308. PubMed ID: 25044709
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
13. Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women.
Luu-The V; Tremblay P; Labrie F
Mol Endocrinol; 2006 Feb; 20(2):437-43. PubMed ID: 16166196
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
Le Lain R; Nicholls PJ; Smith HJ; Maharlouie FH
J Enzyme Inhib; 2001 Jan; 16(1):35-45. PubMed ID: 11496833
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
16. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
17. Specific estradiol biosynthetic pathway in choriocarcinoma (JEG-3) cell line.
Samson M; Labrie F; Luu-The V
J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):154-9. PubMed ID: 19465125
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of 3beta- and 17beta-hydroxysteroid dehydrogenase activities in rat Leydig cells by perfluorooctane acid.
Zhao B; Chu Y; Hardy DO; Li XK; Ge RS
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):13-7. PubMed ID: 19818404
[TBL] [Abstract][Full Text] [Related]
19. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17beta-hydroxysteroid dehydrogenase type 1.
Bérubé M; Poirier D
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):832-43. PubMed ID: 19003559
[TBL] [Abstract][Full Text] [Related]
20. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]